Stock Movers: BioNTech Cancer Drug Deal, Boeing Upgrade, and Trump's Steel Tariffs

BioNTech's Cancer Drug Deal

• 💡 BioNTech (BNTX) shares surged by 20% following a significant licensing deal with Bristol-Myers Squibb.
• 💰 The agreement could be worth up to $11.1 billion, including a $1.5 billion upfront payment, installments through 2028, and substantial milestone payments.
• 🎯 This deal targets the oncology market, which is estimated to reach $60 billion annually by 2027, highlighting the growing competition in using the immune system to fight tumors.

Boeing Receives Analyst Upgrade

• 🚀 Boeing (BA) shares saw a modest gain after BofA Global Research upgraded the stock to 'buy' from 'neutral'.
• 📈 Analyst Ronald Epstein believes Boeing's aircraft are favored by the Trump administration in trade deals, citing the Qatar Airways agreement.
• 🎯 The price target was raised to a street-high of $260, suggesting a potential 25% increase from the current stock price.

Impact of Trump's Steel Tariff Announcement

• 📈 US steel and aluminum stocks, including Nucor, rallied following President Trump's announcement to double steel and aluminum tariffs to 50%.
• ⚠️ This move, made at a US steel plant, aims to protect American workers but contrasts with falling stocks in Asia, Australia, and Canada.
• 🧩 Capital upgraded Nucor to 'outperform' while downgrading Canada's Aloma Steel, suggesting a potential pair trade strategy.
• ❓ The long-term impact on demand and the necessity for US steel prices to rise to offset increased import costs remain key considerations.